Safety Evaluation of Medroxyprogesterone Acetate
Author Information
Author(s): Su Luyang, Xu Ren, Ren Yanan, Zhao Shixia, Liu Weilan, Du Zeqing
Primary Institution: Hebei General Hospital, Shijiazhuang, China
Hypothesis
This study aimed to evaluate the adverse events associated with medroxyprogesterone acetate (MPA) by analyzing real-world data from the FDA's Adverse Event Reporting System (FAERS).
Conclusion
The study identified several previously unreported adverse events associated with MPA, highlighting the need for further research.
Supporting Evidence
- 3,939 women reported using MPA as a contraceptive method.
- Significant adverse events included unintended pregnancy, bone pain, and dental caries.
- The median time-to-onset of adverse events was 195.50 days.
Takeaway
This study looked at the side effects of a birth control shot called medroxyprogesterone acetate and found some unexpected problems that weren't mentioned before.
Methodology
Data from the FAERS database covering 2004 to 2024 was analyzed using statistical methods including reporting odds ratio (ROR) and proportional reporting ratio (PRR).
Potential Biases
Potential bias due to the spontaneous nature of the FAERS database and varying quality of reports.
Limitations
The study relies on voluntary reporting, which may lead to underreporting and bias, and the findings may not be generalizable beyond the U.S.
Participant Demographics
All participants were women, with a significant proportion aged 21-40 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website